PARP1 and neoplasm: We assessed the DNA damage response and tumor growth inhibition in 2 NSCLC xenograft models: Calu-6 xenografts (hypoxic) and Calu-3 xenografts (well-oxygenated), following radiation and the PARP1/2 inhibitor olaparib treatment.